

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 37/46</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/27631</b> <b>(43) International Publication Date:</b> 8 December 1994 (08.12.94)
<b>(21) International Application Number:</b> PCT/US94/05779 <b>(22) International Filing Date:</b> 23 May 1994 (23.05.94)  <b>(30) Priority Data:</b> 08/065,725      21 May 1993 (21.05.93)      US  <b>(71) Applicants (for all designated States except US):</b> ZYMOGENETICS, INC. [US/US]; 4225 Roosevelt Way Northeast, Seattle, WA 98105 (US). NOVO NORDISK A/S [DK/DK]; Novo Alle, DK-2880 Bagsvaerd (DK).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BERKNER, Kathleen, L. [US/US]; 3032-22nd Avenue West, Seattle, WA 98199 (US). PETERSEN, Lars, Christian [DK/DK]; Havevej 4, DK-Hoersholm (DK). HART, Charles, E. [US/US]; 21502 21st Avenue West, Brier, WA 98036 (US).  <b>(74) Agents:</b> PARMELEE, Steven, W. et al.; Townsend and Townsend Khourie and Crew, 20th floor, Steuart Street Tower, One Market Plaza, San Francisco, CA 94105 (US).		<b>(81) Designated States:</b> AU, CA, HU, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> MODIFIED FACTOR VII  <b>(57) Abstract</b>  The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modification render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## MODIFIED FACTOR VII

Related Applications

5           The present invention is a continuation-in-part of  
USSN filed May 21, 1993, which is incorporated herein by  
reference.

Field of the Invention

10           The present invention relates to proteins useful as  
anticoagulants. More specifically, the present invention  
relates to modified forms of Factor VII that inhibit blood  
coagulation and tissue factor.

Background Of The Invention

15           Blood coagulation is a process consisting of a  
complex interaction of various blood components, or factors,  
which eventually gives rise to a fibrin clot. Generally, the  
blood components which participate in what has been referred  
20           to as the coagulation "cascade" are proenzymes or zymogens,  
enzymatically inactive proteins which are converted to  
proteolytic enzymes by the action of an activator, itself an  
activated clotting factor. Coagulation factors that have  
undergone such a conversion and generally referred to as  
25           "active factors," and are designated by the addition of a  
lower case "a" suffix (e.g., Factor VIIa).

          Activated Factor X ("Xa") is required to convert  
prothrombin to thrombin, which then converts fibrinogen to  
fibrin as a final stage in forming a fibrin clot. There are  
30           two systems, or pathways, that promote the activation of  
Factor X. The "intrinsic pathway" refers to those reactions  
that lead to thrombin formation through utilization of factors  
present only in plasma. A series of protease-mediated  
activations ultimately generates Factor IXa which, in  
35           conjunction with Factor VIIIa, cleaves Factor X into Xa. An  
identical proteolysis is effected by Factor VIIa and its co-  
factor, tissue factor, in the "extrinsic pathway" of blood

coagulation. Tissue factor is a membrane bound protein and does not normally circulate in plasma. Upon vessel disruption, however, it can complex with Factor VIIa to catalyze Factor X activation or Factor IX activation in the presence of  $\text{Ca}^{++}$  and phospholipid (Nemerson and Gentry, Biochem. 25:4020-4033 (1986)). While the relative importance of the two coagulation pathways in hemostasis is unclear, in recent years Factor VII and tissue factor have been found to play a pivotal role in the regulation of blood coagulation.

Factor VII is a trace plasma glycoprotein that circulates in blood as a single-chain zymogen. The zymogen is catalytically inactive (Williams et al., J. Biol. Chem. 264:7536-7543 (1989); Rao et al., Proc. Natl. Acad. Sci. USA. 85:6687-6691 (1988)). Single-chain Factor VII may be converted to two-chain Factor VIIa by Factor Xa, Factor XIIa, Factor IXa or thrombin in vitro. Factor Xa is believed to be the major physiological activator of Factor VII. Like several other plasma proteins involved in hemostasis, Factor VII is dependent on vitamin K for its activity, which is required for the  $\gamma$ -carboxylation of multiple glutamic acid residues that are clustered in the amino terminus of the protein. These  $\gamma$ -carboxylated glutamic acids are required for the metal-associated interaction of Factor VII with phospholipids.

The conversion of zymogen Factor VII into the activated two-chain molecule occurs by cleavage of an internal peptide bond located approximately in the middle of the molecule. In human Factor VII, the activation cleavage site is at Arg<sub>152</sub>-Ile<sub>153</sub> (Hagen et al., Proc. Natl. Acad. Sci. USA 83: 2412-2416 (1986); Thim et al., Biochem. 27:7785-7793 (1988) both of which are incorporated herein by references). Bovine factor VII is activated by cleavage at the analogous Arg<sub>152</sub>-Ile<sub>153</sub> bond (Takeya et al., J. Biol. Chem. 263: 14868-14877, 1988). In the presence of tissue factor, phospholipids and calcium ions, the two-chain Factor VIIa rapidly activates Factor X or Factor IX by limited proteolysis.

It is often necessary to selectively block the coagulation cascade in a patient. Anticoagulants such as

heparin, coumarin, derivatives of coumarin, indandione derivatives, or other agents may be used, for example, during kidney dialysis, or to treat deep vein thrombosis, disseminated intravascular coagulation (DIC), and a host of other medical disorders. For example, heparin treatment or extracorporeal treatment with citrate ion (U.S. Patent 4,500,309) may be used in dialysis to prevent coagulation during the course of treatment. Heparin is also used in preventing deep vein thrombosis in patients undergoing surgery.

Treatment with heparin and other anticoagulants may, however, have undesirable side effects. Available anticoagulants generally act throughout the body, rather than acting specifically at a clot site. Heparin, for example, may cause heavy bleeding. Furthermore, with a half-life of approximately 80 minutes, heparin is rapidly cleared from the blood, necessitating frequent administration. Because heparin acts as a cofactor for antithrombin III (AT III), and AT III is rapidly depleted in DIC treatment, it is often difficult to maintain the proper heparin dosage, necessitating continuous monitoring of AT III and heparin levels. Heparin is also ineffective if AT III depletion is extreme. Further, prolonged use of heparin may also increase platelet aggregation and reduce platelet count, and has been implicated in the development of osteoporosis. Indandione derivatives may also have toxic side effects.

In addition to the anticoagulants briefly described above, several naturally occurring proteins have been found to have anticoagulant activity. For example, Reutelingsperger (U.S. Patent No. 4,736,018) isolated anticoagulant proteins from bovine aorta and human umbilical vein arteries. Maki et al. (U.S. Patent No. 4,732,891) disclose human placenta-derived anticoagulant proteins. In addition, AT III has been proposed as a therapeutic anticoagulant (Schipper et al., Lancet 1 (8069): 854-856 (1978); Jordan, U.S. Patent No. 4,386,025; Bock et al., U.S. Patent No. 4,517,294).

Proliferation of smooth muscle cells (SMCs) in the vessel wall is an important event in the formation of vascular lesions in atherosclerosis, after vascular reconstruction or in response to other vascular injury. For example, treatment of atherosclerosis frequently includes the clearing of blocked vessels by angioplasty, endarterectomy or reduction atherectomy, or by bypass grafting, surgical procedures in which atherosclerotic plaques are compressed or removed through catheterization (angioplasty), stripped away from the arterial wall through an incision (endarterectomy) or bypassed with natural or synthetic grafts. These procedures remove the vascular endothelium, disturb the underlying intimal layer, and result in the death of medial SMCs. This injury is followed by medial SMC proliferation and migration into the intima, which characteristically occurs within the first few weeks and up to six months after injury and stops when the overlying endothelial layer is reestablished. In humans, these lesions are composed of about 20% cells and 80% extracellular matrix.

In about 30% or more of patients treated by angioplasty, endarterectomy or bypass grafts, thrombosis and/or SMC proliferation in the intima causes re-occlusion of the vessel and consequent failure of the reconstructive surgery. This closure of the vessel subsequent to surgery is known as restenosis.

There is still a need in the art for improved compositions having anticoagulant activity which can be administered at relatively low doses and do not produce the undesirable side effects associated with traditional anticoagulant compositions. The present invention fulfills this need by providing anticoagulants that act specifically at sites of injury, and further provides other related advantages.

Summary Of The Invention

Novel compositions which comprise modified Factor VII having anticoagulant properties are provided. The modified Factor VII compositions also inhibit tissue factor.

5 The Factor VII sequence has at least one amino acid modification, where the modification is selected so as to substantially reduce the ability of activated Factor VII to catalyze the activation of plasma Factors X or IX, and thus is capable of inhibiting clotting activity. The novel Factor VII

10 has an active site modified by at least one amino acid substitution, and in its modified form is capable of binding tissue factor. The modified Factor VII compositions are typically in substantially pure form.

The compositions of the invention are particularly

15 useful in methods for treating patients when formulated into pharmaceutical compositions, where they may be given to individuals suffering from a variety of disease states to treat coagulation-related conditions. Such modified Factor VII molecules, capable of binding tissue factor but having a

20 substantially reduced ability to catalyze activation of other factors in the clotting cascade, may possess a longer plasma half-life and thus a correspondingly longer period of anticoagulative activity when compared to other anticoagulants. Among the medical indications for the subject

25 compositions are those commonly treated with anticoagulants, such as, for example, deep vein thrombosis, pulmonary embolism, stroke, disseminated intravascular coagulation (DIC) and myocardial infarction. The compositions can be used to inhibit vascular restenosis and platelet deposition and

30 associated disorders. Thus, a method of inhibiting coagulation, vascular restenosis or platelet deposition, for example, comprises administering to a patient a composition comprising modified Factor VII, such as that having at least one amino acid substitution in a catalytic triad of Ser<sub>344</sub>,

35 Asp<sub>242</sub> and His<sub>193</sub>, in an amount sufficient to effectively inhibit coagulation, vascular restenosis or platelet deposition, respectively.

Typically, for administration to humans the pharmaceutical compositions will comprise modified human Factor VII protein and pharmaceutically-acceptable carriers and buffers.

5 In preferred embodiments of human and bovine Factor VII, the active site residue Ser<sub>344</sub> is modified, replaced with Gly, Met, Thr, or more preferably, Ala. Such substitution could be made separately or in combination with substitution(s) at other sites in the catalytic triad, which  
10 includes His<sub>193</sub> and Asp<sub>242</sub>.

In another aspect the invention relates to a polynucleotide molecule comprising two operatively linked sequence coding regions encoding, respectively, a pre-pro peptide and a gla domain of a vitamin K-dependent plasma  
15 protein, and a gla domain-less Factor VII protein, wherein upon expression said polynucleotide encodes a modified Factor VII molecule which does not significantly activate plasma Factors X or IX, and is capable of binding tissue factor. The modified Factor VII molecule expressed by this polynucleotide  
20 is a biologically active anticoagulant, that is, it is capable of inhibiting the coagulation cascade and thus the formation of a fibrin deposit or clot. To express the modified Factor VII the polynucleotide molecule is transfected into mammalian cell lines, such as, for example, BHK, BHK 570 or 293 cell  
25 lines.

#### Brief Description Of The Figure

The Figure illustrates the construction of an expression vector for a Ser<sub>344</sub>→Ala modified Factor VII DNA  
30 sequence. Symbols used include 0-1, the 0-1 map unit sequence from adenovirus 5; E, the SV40 enhancer; MLP, the adenovirus 2 major late promotor; SS, a set of splice sites; and pA, the polyadenylation signal from SV40 in the late orientation.

#### Description Of The Specific Embodiments

35 Novel modified Factor VII having anticoagulant activity is provided by the present invention. The modified

Factor VII can be in the form of the zymogen (i.e., a single-chain molecule) or can be cleaved at its activation site. Compositions of the modified Factor VII are suitable for administration to a variety of mammals, particularly humans, to inhibit the coagulation cascade. Modified Factor VII may be administered to a patient in conjunction with or in place of other anticoagulant compounds.

Factor VII plays an important role in the coagulation cascade, particularly that involving the extrinsic pathway. Present in the circulating plasma as an inactive single chain zymogen protein, once activated, Factor VIIa, in combination with tissue factor and calcium ions, activates Factor X to Xa and activates Factor IX to IXa, with the eventual formation of a fibrin clot.

The present invention provides the ability to inhibit this sequence of events in the coagulation cascade by preventing or otherwise inhibiting the activation of Factors X and IX by Factor VIIa. Factor VII proteins of the invention have a catalytic site which is modified to decrease the catalytic activity of Factor VIIa, while the molecule retains the ability to bind to tissue factor. The modified Factor VII molecules compete with native Factor VII and/or VIIa for binding to tissue factor. As a result, the activation of Factors X and IX is inhibited.

In one aspect of the present invention the catalytic activity of Factor VIIa is inhibited by chemical derivatization of the catalytic center, or triad. Derivatization may be accomplished by reacting Factor VII with an irreversible inhibitor such as an organophosphor compound, a sulfonyl fluoride, a peptide halomethyl ketone or an azapeptide, or by acylation, for example. Preferred peptide halomethyl ketones include PPACK (D-Phe-Pro-Arg chloromethyl ketone; see U.S. Patent No. 4,318,904, incorporated herein by reference), and DEGRck (dansyl-Glu-Gly-Arg chloromethyl ketone).

In another aspect, the catalytic activity of Factor VIIa can also be inhibited by substituting, inserting or

deleting amino acids. In preferred embodiments amino acid substitutions are made in the amino acid sequence of the Factor VII catalytic triad, defined herein as the regions which contain the amino acids which contribute to the Factor VIIa catalytic site. The substitutions, insertions or deletions in the catalytic triad are generally at or adjacent to the amino acids which form the catalytic site. In the human and bovine Factor VII proteins, the amino acids which form a catalytic "triad" are Ser<sub>344</sub>, Asp<sub>242</sub>, and His<sub>193</sub> (subscript numbering indicating position in the sequence). The catalytic sites in Factor VII from other mammalian species may be determined using presently available techniques including, among others, protein isolation and amino acid sequence analysis. Catalytic sites may also be determined by aligning a sequence with the sequence of other serine proteases, particularly chymotrypsin, whose active site has been previously determined (Sigler et al., J. Mol. Biol., 35:143-164 (1968), incorporated herein by reference), and therefrom determining from said alignment the analogous active site residues.

The amino acid substitutions, insertions or deletions are made so as to prevent or otherwise inhibit activation by the Factor VIIa of Factors X and/or IX. The Factor VII so modified should, however, also retain the ability to compete with authentic Factor VII and/or Factor VIIa for binding to tissue factor in the coagulation cascade. Such competition may readily be determined by means of, e.g., a clotting assay as described herein, or a competition binding assay using, e.g., a cell line having cell-surface tissue factor, such as the human bladder carcinoma cell line J82 (Sakai et al. J. Biol. Chem. 264: 9980-9988 (1989), incorporated by reference herein.)

The amino acids which form the catalytic site in Factor VII, such as Ser<sub>344</sub>, Asp<sub>242</sub>, and His<sub>193</sub> in human and bovine Factor VII, may either be substituted or deleted. Within the present invention, it is preferred to change only a single amino acid, thus minimizing the likelihood of

increasing the antigenicity of the molecule or inhibiting its ability to bind tissue factor, however two or more amino acid changes (substitutions, additions or deletions) may be made and combinations of substitution(s), addition(s) and deletion(s) may also be made. In a preferred embodiment for human and bovine Factor VII, Ser<sub>344</sub> is preferably substituted with Ala, but Gly, Met, Thr or other amino acids can be substituted. It is preferred to replace Asp with Glu and to replace His with Lys or Arg. In general, substitutions are chosen to disrupt the tertiary protein structure as little as possible. The model of Dayhoff et al. (in Atlas of Protein Structure 1978, Nat'l Biomed. Res. Found., Washington, D.C.), incorporated herein by reference, may be used as a guide in selecting other amino acid substitutions. One may introduce residue alterations as described above in the catalytic site of appropriate Factor VII sequence of human, bovine or other species and test the resulting protein for a desired level of inhibition of catalytic activity and resulting anticoagulant activity as described herein. For the modified Factor VII the catalytic activity will be substantially inhibited, generally less than about 5% of the catalytic activity of wild-type Factor VII of the corresponding species, more preferably less than about 1%.

The proteins of the present invention may be produced through the use of recombinant DNA techniques. In general, a cloned wild-type Factor VII DNA sequence is modified to encode the desired protein. This modified sequence is then inserted into an expression vector, which is in turn transformed or transfected into host cells. Higher eukaryotic cells, in particular cultured mammalian cells, are preferred as host cells. The complete nucleotide and amino acid sequences for human Factor VII are known. See U.S. Pat. No. 4,784,950, which is incorporated herein by reference, where the cloning and expression of recombinant human Factor VII is described. The bovine Factor VII sequence is described in Takeya et al., J. Biol. Chem. 263:14868-14872 (1988), which is incorporated by reference herein.

The amino acid sequence alterations may be accomplished by a variety of techniques. Modification of the DNA sequence may be by site-specific mutagenesis. Techniques for site-specific mutagenesis are well known in the art and are described by, for example, Zoller and Smith (DNA 3:479-488, 1984). Thus, using the nucleotide and amino acid sequences of Factor VII, one may introduce the alteration(s) of choice.

The Factor VII modified according to the present invention includes those proteins that have the amino-terminal portion (gla domain) substituted with a gla domain of one of the vitamin K-dependent plasma proteins Factor IX, Factor X, prothrombin, protein C, protein S or protein Z. The gla domains of the vitamin K-dependent plasma proteins are characterized by the presence of gamma-carboxy glutamic acid residues and are generally from about 30 to about 40 amino acids in length with C-termini corresponding to the positions of exon-intron boundaries in the respective genes. Methods for producing Factor VII with a heterologous gla domain are disclosed in U.S. Patent No. 4,784,950, incorporated by reference herein.

DNA sequences for use within the present invention will typically encode a pre-pro peptide at the amino-terminus of the Factor VII protein to obtain proper post-translational processing (e.g. gamma-carboxylation of glutamic acid residues) and secretion from the host cell. The pre-pro peptide may be that of Factor VII or another vitamin K-dependent plasma protein, such as Factor IX, Factor X, prothrombin, protein C or protein S. As will be appreciated by those skilled in the art, additional modifications can be made in the amino acid sequence of the modified Factor VII where those modifications do not significantly impair the ability of the protein to act as an anticoagulant. For example, the Factor VII modified in the catalytic triad can also be modified in the activation cleavage site to inhibit the conversion of zymogen Factor VII into its activated two-

chain form, as generally described in U.S. Patent 5,288,629, incorporated herein by reference.

Expression vectors for use in carrying out the present invention will comprise a promoter capable of directing the transcription of a cloned gene or cDNA. Preferred promoters for use in cultured mammalian cells include viral promoters and cellular promoters. Viral promoters include the SV40 promoter (Subramani et al., Mol. Cell. Biol. 1:854-864, 1981) and the CMV promoter (Boshart et al., Cell 41:521-530, 1985). A particularly preferred viral promoter is the major late promoter from adenovirus 2 (Kaufman and Sharp, Mol. Cell. Biol. 2:1304-1319, 1982). Cellular promoters include the mouse kappa gene promoter (Bergman et al., Proc. Natl. Acad. Sci. USA 81:7041-7045, 1983) and the mouse V<sub>H</sub> promoter (Loh et al., Cell 33:85-93, 1983). A particularly preferred cellular promoter is the mouse metallothionein-I promoter (Palmiter et al., Science 222:809-814, 1983). Expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the insertion site for the Factor VII sequence itself. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the insertion site. Particularly preferred polyadenylation signals include the early or late polyadenylation signal from SV40 (Kaufman and Sharp, *ibid.*), the polyadenylation signal from the adenovirus 5 Elb region, the human growth hormone gene terminator (DeNoto et al. Nuc. Acids Res. 9:3719-3730, 1981) or the polyadenylation signal from the human Factor VII gene or the bovine Factor VII gene. The expression vectors may also include a noncoding viral leader sequence, such as the adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites; and enhancer sequences, such as the SV40 enhancer.

Cloned DNA sequences are introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14:725-732, 1978; Corsaro

and Pearson, Somatic Cell Genetics 7:603-616, 1981; Graham and Van der Eb, Virology 52d:456-467, 1973) or electroporation (Neumann et al., EMBO J. 1:841-845, 1982). To identify and select cells that express the exogenous DNA, a gene that  
5 confers a selectable phenotype (a selectable marker) is generally introduced into cells along with the gene or cDNA of interest. Preferred selectable markers include genes that confer resistance to drugs such as neomycin, hygromycin, and methotrexate. The selectable marker may be an amplifiable  
10 selectable marker. A preferred amplifiable selectable marker is a dihydrofolate reductase (DHFR) sequence. Selectable markers are reviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers, Stoneham, MA, incorporated herein by reference). The choice of selectable markers is well within  
15 the level of ordinary skill in the art.

Selectable markers may be introduced into the cell on a separate plasmid at the same time as the gene of interest, or they may be introduced on the same plasmid. If  
20 on the same plasmid, the selectable marker and the gene of interest may be under the control of different promoters or the same promoter, the latter arrangement producing a dicistronic message. Constructs of this type are known in the art (for example, Levinson and Simonsen, U.S. Patent  
4,713,339). It may also be advantageous to add additional  
25 DNA, known as "carrier DNA," to the mixture that is introduced into the cells.

After the cells have taken up the DNA, they are grown in an appropriate growth medium, typically 1-2 days, to begin expressing the gene of interest. As used herein the  
30 term "appropriate growth medium" means a medium containing nutrients and other components required for the growth of cells and the expression of the modified Factor VII gene. Media generally include a carbon source, a nitrogen source, essential amino acids, essential sugars, vitamins, salts,  
35 phospholipids, protein and growth factors. For production of gamma-carboxylated modified Factor VII, the medium will contain vitamin K, preferably at a concentration of about 0.1

$\mu\text{g/ml}$  to about 5  $\mu\text{g/ml}$ . Drug selection is then applied to select for the growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an amplifiable selectable marker the drug concentration may be increased to select for an increased copy number of the cloned sequences, thereby increasing expression levels. Clones of stably transfected cells are then screened for expression of modified Factor VII.

Preferred mammalian cell lines for use in the present invention include the COS-1 (ATCC CRL 1650), baby hamster kidney (BHK) and 293 (ATCC CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977) cell lines. A preferred BHK cell line is the tk<sup>-</sup> ts13 BHK cell line (Waechter and Baserga, Proc. Natl. Acad. Sci. USA 79:1106-1110, 1982, incorporated herein by reference), hereinafter referred to as BHK 570 cells. The BHK 570 cell line has been deposited with the American Type Culture Collection, 12301 Parklawn Dr., Rockville, MD 20852, under ATCC accession number CRL 10314. A tk<sup>-</sup> ts13 BHK cell line is also available from the ATCC under accession number CRL 1632. In addition, a number of other cell lines may be used within the present invention, including Rat Hep I (Rat hepatoma; ATCC CRL 1600), Rat Hep II (Rat hepatoma; ATCC CRL 1548), TCMK (ATCC CCL 139), Human lung (ATCC HB 8065), NCTC 1469 (ATCC CCL 9.1), CHO (ATCC CCL 61) and DUKX cells (Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216-4220, 1980).

Modified Factor VII produced according to the present invention may be purified by affinity chromatography on an anti-Factor VII antibody column. The use of calcium-dependent monoclonal antibodies, as described by Wakabayashi et al., J. Biol. Chem. 261:11097-11108, (1986) and Thim et al., Biochem. 27: 7785-7793, (1988), incorporated by reference herein, is particularly preferred. Additional purification may be achieved by conventional chemical purification means, such as high performance liquid chromatography. Other methods of purification, including barium citrate precipitation, are known in the art, and may be applied to the purification of

the novel modified Factor VII described herein (see, generally, Scopes, R., Protein Purification, Springer-Verlag, N.Y., 1982). Substantially pure modified Factor VII of at least about 90 to 95% homogeneity is preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the modified Factor VII may then be used therapeutically.

Within one embodiment of the invention the modified Factor VII is cleaved at its activation site to convert it to its two-chain form. Activation may be carried out according to procedures known in the art, such as those disclosed by Osterud, et al., Biochemistry 11:2853-2857 (1972); Thomas, U.S. Patent No. 4,456,591; Hedner and Kisiel, J. Clin. Invest. 71:1836-1841 (1983); or Kisiel and Fujikawa, Behring Inst. Mitt. 73:29-42 (1983), which are incorporated herein by reference. The resulting modified "Factor VIIa" is then formulated and administered as described below.

The modified Factor VII or VIIa molecules of the present invention and pharmaceutical compositions thereof are particularly useful for administration to humans to treat a variety of conditions involving intravascular coagulation. For example, although deep vein thrombosis and pulmonary embolism can be treated with conventional anticoagulants, the modified Factor VII or VIIa described herein may be used to prevent the occurrence of thromboembolic complications in identified high risk patients, such as those undergoing surgery or those with congestive heart failure. In addition, modified Factor VII or VIIa may act as an antagonist for tissue factor-mediated induction of coagulation, thus blocking the production of thrombin and the subsequent deposition of fibrin. As such, modified Factor VII or VIIa may be useful for inhibiting tissue factor activity resulting in, for example, the inhibition of blood coagulation, thrombosis or platelet deposition.

The modified Factor VII or VIIa molecules of the present invention may be particularly useful in the treatment of intimal hyperplasia or restenosis due to acute vascular

injury. Acute vascular injuries are those which occur rapidly (i.e. over days to months), in contrast to chronic vascular injuries (e.g. atherosclerosis) which develop over a lifetime. Acute vascular injuries often result from surgical procedures such as vascular reconstruction, wherein the techniques of angioplasty, endarterectomy, atherectomy, vascular graft emplacement or the like are employed. Hyperplasia may also occur as a delayed response in response to, e.g., graft emplacement or organ transplantation. Since modified Factor VII is more selective than heparin, generally binding only tissue factor which has been exposed at sites of injury, and because modified Factor VII does not destroy other coagulation proteins, it will be more effective and less likely to cause bleeding complications than heparin when used prophylactically for the prevention of deep vein thrombosis. The dose of modified Factor VII for prevention of deep vein thrombosis is in the range of about 50  $\mu$ g to 25 mg/day, preferably 1 to 10 mg/day for a 70 kg patient, and administration should begin at least about 6 hours prior to surgery and continue at least until the patient becomes ambulatory. The dose of modified Factor VII or VIIa in the treatment for restenosis will vary with each patient but will generally be in the range of those suggested above.

Recent advances in the treatment of coronary vascular disease include the use of mechanical interventions to either remove or displace offending plaque material in order to re-establish adequate blood flow through the coronary arteries. Despite the use of multiple forms of mechanical interventions, including balloon angioplasty, reduction atherectomy, placement of vascular stents, laser therapy, or rotoblator, the effectiveness of these techniques remains limited by an approximately 40% restenosis rate within 6 months after treatment.

Restenosis is thought to result from a complex interaction of biological processes including platelet deposition and thrombus formation, release of chemotactic and mitogenic factors, and the migration and proliferation of

vascular smooth muscle cells into the intima of the dilated arterial segment.

5 The inhibition of platelet accumulation at sites of mechanical injury can limit the rate of restenosis in human subjects. Therapeutic use of a monoclonal antibody to platelet GpIIb/IIIa is able to limit the level of restenosis in human subjects (Califf et al., N. Engl. J. Med., 330:956-961 (1994)). The antibody is able to bind to the GpIIb/IIIa receptor on the surfaces of platelets and thereby inhibit  
10 platelet accumulation. This data suggests that inhibition of platelet accumulation at the site of mechanical injury in human coronary arteries is beneficial for the ultimate healing response that occurs. While platelet accumulation occurs at sites of acute vascular injuries, the generation of thrombin  
15 at these sites may be responsible for the activation of the platelets and their subsequent accumulation.

As shown in the examples that follow, the modified Factor VIIa of the present invention is able to bind to cell-surface tissue factor. For example, DEGR-Factor VIIa binds  
20 cell-surface tissue factor with an equivalent or higher affinity than wild-type Factor VIIa. DEGR-Factor VIIa, however, has no enzymatic activity, yet it binds to tissue factor and acts as a competitive antagonist for wild-type Factor VIIa, thereby inhibiting the subsequent steps in the  
25 extrinsic pathway of coagulation leading to the generation of thrombin.

Modified Factor VIIa molecules of the present invention which maintain tissue factor inhibit platelet accumulation at the site of vascular injury by blocking the  
30 production of thrombin and the subsequent deposition of fibrin.

Due to the ability of DEGR-Factor VIIa to block thrombin generation and limit platelet deposition at sites of acute vascular injury, modified Factor VIIa molecules maintain  
35 tissue factor binding activity but lack Factor VIIa enzymatic activity can be used to inhibit vascular restenosis.

In established deep vein thrombosis and/or pulmonary embolism, the dose of modified Factor VII ranges from about 50  $\mu$ g to 25 mg as a loading dose followed by maintenance doses ranging from about 500  $\mu$ g to 10 mg/day, depending on the weight of the patient and the severity of the condition. Because of the lower likelihood of bleeding complications from modified Factor VII infusions, modified Factor VII can replace or lower the dose of heparin during or after surgery in conjunction with thrombectomies or embolectomies.

The modified Factor VII compositions of the present invention will also have substantial utility in the prevention of cardiogenic emboli and in the treatment of thrombotic strokes. Because of its low potential for causing bleeding complications and its selectivity, modified Factor VII can be given to stroke victims and may prevent the extension of the occluding arterial thrombus. The amount of modified Factor VII administered will vary with each patient depending on the nature and severity of the stroke, but doses will generally be in the range of those suggested below.

Pharmaceutical compositions of modified Factor VII provided herein will be a useful treatment in acute myocardial infarction because of the ability of modified Factor VII to inhibit in vivo coagulation. Modified Factor VII can be given with tissue plasminogen activator or streptokinase during the acute phases of the myocardial infarction. In acute myocardial infarction, the patient is given a loading dose of at least about 1 to 25 mg of modified Factor VII, followed by maintenance doses of about 500  $\mu$ g to about 10 mg/day.

The modified Factor VII of the present invention is useful in the treatment of disseminated intravascular coagulation (DIC). Patients with DIC characteristically have widespread microcirculatory thrombi and often severe bleeding problems which result from consumption of essential clotting factors. Because of its selectivity, modified Factor VII will not aggravate the bleeding problems associated with DIC, as do conventional anticoagulants, but will retard or inhibit the formation of additional microvascular fibrin deposits.

The pharmaceutical compositions are intended for parenteral, topical or local administration for prophylactic and/or therapeutic treatment. Preferably, the pharmaceutical compositions are administered parenterally, i.e.,

5 intravenously, subcutaneously, or intramuscularly. Thus, this invention provides compositions for parenteral administration which comprise a solution of the modified Factor VII molecules dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g.,

10 water, buffered water, 0.4% saline, 0.3% glycine and the like. The modified Factor VII molecules can also be formulated into liposome preparations for delivery or targeting to sites of injury. Liposome preparations are generally described in, e.g., U.S. 4,837,028, U.S. 4,501,728, and U.S. 4,975,282,

15 incorporated herein by reference. The compositions may be sterilized by conventional, well known sterilization techniques. The resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile

20 aqueous solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate,

25 sodium chloride, potassium chloride, calcium chloride, etc. The concentration of modified Factor VII in these formulations can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily by fluid volumes, viscosities,

30 etc., in accordance with the particular mode of administration selected.

Thus, a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 10 mg of modified Factor VII.

35 Actual methods for preparing parenterally administrable compounds will be known or apparent to those skilled in the art and are described in more detail in for example,

Remington's Pharmaceutical Science, 16th ed., Mack Publishing Company, Easton, PA (1982), which is incorporated herein by reference.

5           The compositions containing the modified Factor VII  
molecules can be administered for prophylactic and/or  
therapeutic treatments. In therapeutic applications,  
compositions are administered to a patient already suffering  
from a disease, as described above, in an amount sufficient to  
cure or at least partially arrest the disease and its  
10        complications. An amount adequate to accomplish this is  
defined as "therapeutically effective dose." Amounts  
effective for this use will depend on the severity of the  
disease or injury and the weight and general state of the  
patient, but generally range from about 0.05 mg to about 25 mg  
15        of modified Factor VII per day for a 70 kg patient, with  
dosages of from about 0.5 mg to about 10 mg of modified Factor  
VII per day being more commonly used. It must be kept in mind  
that the materials of the present invention may generally be  
employed in serious disease or injury states, that is, life-  
20        threatening or potentially life threatening situations. In  
such cases, in view of the minimization of extraneous  
substances and general lack of immunogenicity of modified  
human Factor VII in humans, it is possible and may be felt  
desirable by the treating physician to administer substantial  
25        excesses of these modified Factor VII compositions.

          In prophylactic applications, compositions  
containing the modified Factor VII are administered to a  
patient susceptible to or otherwise at risk of a disease state  
or injury to enhance the patient's own anticoagulative  
30        capabilities. Such an amount is defined to be a  
"prophylactically effective dose." In this use, the precise  
amounts again depend on the patient's state of health and  
weight, but generally range from about 0.1 mg to about 25 mg  
per 70 kilogram patient, more commonly from about 0.5 mg to  
35        about 10 mg per 70 kg of body weight.

          Single or multiple administrations of the  
compositions can be carried out with dose levels and pattern

being selected by the treating physician. For ambulatory patients requiring daily maintenance levels, the modified Factor VII may be administered by continuous infusion using a portable pump system, for example. Local delivery of the modified Factor VII or VIIa may be carried out, for example, by way of perfusion, double balloon catheters, stent or other well established methods. In any event, the pharmaceutical formulations should provide a quantity of modified Factor VII of this invention sufficient to effectively treat the patient.

The following examples are offered by way of illustration, not by way of limitation.

#### EXAMPLE I

##### Expression of Ser<sub>344</sub>→Ala<sub>344</sub> Factor VII

To generate the Ser<sub>344</sub>→Ala Factor VII active site mutant, plasmid FVII(565+2463)/ pDX (U.S. Patent No. 4,784,950 incorporated herein by reference; deposited with the American Type Culture Collection under accession number 40205) was digested with Xba I and Kpn I, and the resulting 0.6 kb fragment, comprising the coding region for serine 344, was recovered. This fragment was cloned into Xba I, Kpn I-digested M13mp19 as shown in the Figure. This manipulation and subsequent steps described below were generally performed according to standard protocols (as described, for example, by Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1982) incorporated herein by reference).

Mutagenesis was carried out on the M13 template according to the methods of Zoller and Smith, supra, using the mutagenic oligonucleotide ZC1656 (5' TGG GCC TCC GGC GTC CCC CTT 3') and the "universal" second primer ZC87 (5' TCC CAG TCA CGA CGT 3'). Reaction products were screened using kinased ZC1656. Positive plaques were picked, and template DNA was prepared and sequenced from the Pst I site at 1077 to the Kpn I site at 1213. Sequence analysis confirmed the presence of the desired mutation. The mutant clone was designated 1656.

An expression vector was then constructed using the 1656 clone. The mutagenized sequence was isolated from the M13 vector as a ~0.14 kb Pst I-Kpn I fragment. This fragment was ligated to the 1.7 kb Hind III-Xba I fragment from FVII(565+2463)/pDX, the 0.5 kb Xba I-Pst I fragment from FVII(565+2463)/pDX, and the 4.3 kb Kpn I-Hind III fragment from FVII(565+2463)/pDX, as shown in the Figure. The presence of the desired mutant sequence was confirmed by digesting mutant and wild-type clones with Pst I, and a mutant Factor VII insert in M13 with Kpn I and Xba I, preparing Southern blots of the digested DNA, and probing the blots with radiolabeled ZC1656.

The baby hamster kidney cell line BHK 570 (deposited with the American Type Culture Collection under accession number 10314) was transfected with two isolates (designated #544 and #545) of the 1656 expression vector. The cells were prepared by diluting a confluent 10 cm plate of BHK 570 cells 1:10 into five 10 cm plates in non-selective medium (Dulbecco's modified Eagle's medium [DMEM] containing 10% fetal bovine serum and 1% PSN antibiotic mix [GIBCO Life Technologies, Gaithersburg, MD]). After 24 hours, when the cells had reached 20-30% confluency, they were co-transfected with one isolate of the expression vector encoding the 1656 mutation, plasmid p486 (comprising the Adenovirus 5 ori, SV40 enhancer, Adenovirus 2 major late promotor, Adenovirus 2 tripartite leader, 5' and 3' splice sites, the DHFR<sup>r</sup> cDNA and SV40 polyadenylation signal in pML-1 (Lusky and Botchan, Nature 293: 79-81, (1981)) and 10 µg of carrier DNA (sonicated salmon sperm DNA) as shown in Table 1. The DNA was added to a 15 ml tube, then 0.5 ml of 2X Hepes (25 g Hepes, 40 g NaCl, 1.8 g KCl, 0.75 g Na<sub>2</sub>HPO<sub>4</sub>·2H<sub>2</sub>O, 5 g dextrose diluted to 2.5 l with distilled water and pH adjusted to pH 6.95-7.0) was added and the tubes were mixed. The DNA in each tube was precipitated by the addition of 0.5 ml of 0.25 M CaCl<sub>2</sub> while air was bubbled through the DNA/Hepes solution with a pasteur pipet. The tubes were then vortexed, incubated at room temperature for 15 minutes, and vortexed again. The DNA

mixtures were then added dropwise onto the plates of cells with a pipette. The plates were swirled and incubated at 37°C for 4-6 hours. After incubation, 2 ml of 20% glycerol diluted in Tris-saline (0.375 g KCl, 0.71 g Na<sub>2</sub>HPO<sub>4</sub>, 8.1 g NaCl, 3.0 g Tris-HCl, 0.5 g sucrose, diluted in a total of 1 liter and pH adjusted to pH 7.9) was then added to each plate. The plates were swirled and left at room temperature for two minutes. The medium was then removed from the plates and replaced with 2 ml of Tris-saline. The plates were left at room temperature for 2 minutes, then the Tris-saline was removed and replaced with 10 ml of non-selective medium. The plates were incubated at 37°C for two days.

Table 1				
<u>Transfection*</u>				
<u>Plasmid Name</u>	<u>544</u>	<u>545</u>	<u>544 Control</u>	<u>545 Control</u>
Clone 544	15 $\mu$ l	---	15 $\mu$ l	---
Clone 545	---	30 $\mu$ l	---	30 $\mu$ l
p486	1.5 $\mu$ l	1.5 $\mu$ l	---	---
Carrier DNA	1.6 $\mu$ l	1.6 $\mu$ l	1.6 $\mu$ l	1.6 $\mu$ l

\* DNA concentrations used were: clone 544, 0.7  $\mu$ g/ $\mu$ l; clone 545, 0.3  $\mu$ g/ $\mu$ l; p486, 1.49  $\mu$ g/ $\mu$ l.

After the two day incubation, the cells were diluted in selection medium (DMEM containing 10% dialyzed fetal bovine serum, 1% PSN antibiotic mix and 150 nM methotrexate) and plated at dilutions of 1:100, 1:250 and 1:500 in maxi plates. The plates were incubated at 37°C for one week. After one week, the medium was changed and replaced with selection medium, and the plates were checked for colony formation.

Eight days later, after colony formation, twelve colonies were randomly chosen from the 1:500 dilution plates of the #544 and #545 transfection plates. Each clone was plated into one well of a 6-well plate and grown in selection medium. After seven days, the plates were confluent, and the clones were each split into 10 cm plates in selection medium.

The clones described above and control cells transfected to express wild-type factor VII were metabolically labeled with <sup>35</sup>S-Methionine-Cysteine Protein Labeling Mix (NEN

DuPont Biotechnology Systems, Wilmington, DE). The clones were grown and prepared for a pulse label experiment in selective medium. The cells were rinsed with phosphate buffered saline (Sigma, St. Louis, MO) and pulsed for four hours in 20  $\mu$ Ci/ml  $^{35}$ S-Cys- $^{35}$ S-Met. After four hours, supernatants and cells were harvested. The cells were lysed essentially as described by Lenk and Penman (Cell 16: 289-302, (1979)) and 400  $\mu$ l of each lysate and precleared with 50  $\mu$ l of staph A (Sigma, St. Louis, MO).

Samples from the metabolically labeled cells were radioimmunoprecipitated (RIP) by first incubating the samples with 6  $\mu$ l of anti-Factor VII polyclonal antisera for four hours. Sixty microliters of washed staphylococcal protein A was added to each sample, and the samples were rocked for 1.5 hours at 4°C. The samples were centrifuged, and the supernatant was removed. The pellets were washed twice in 0.7 M RIPA buffer (10 mM Tris, pH 7.4, 1% deoxycholic acid [Calbiochem Corp., La Jolla, CA], 1% Triton X-100, 0.1% SDS, 5 mM EDTA, 0.7 M NaCl) and once in 0.15 M RIPA buffer (10 mM Tris, pH 7.4, 1% deoxycholic acid [Calbiochem Corp., La Jolla, CA], 1% Triton X-100, 0.1 SDS, 5 mM EDTA, 0.15 M NaCl). One hundred microliters of 1x SDS dye (50 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromphenol blue, 10% glycerol) was added to each sample, and the samples were boiled for 5 minutes followed by centrifugation to remove the protein A. Fifty microliters of each sample was run on a 10% polyacrylamide gel. Results showed that 9 of 10 clones secreted modified Factor VII.

## EXAMPLE II

### ANTICOAGULANT ACTIVITY OF MODIFIED FACTOR VII

The ability of the modified Factor VII protein to inhibit clotting was measured in a one-stage clotting assay using wild-type Factor VII as a control. Recombinant proteins were prepared essentially as described above from cells cultured in media containing 5 $\mu$ g/ml vitamin K. Varying amounts of the modified Factor VII (from clone 544) or

recombinant wild-type Factor VII were diluted in 50 mM Tris pH 7.5, 0.1% BSA to 100  $\mu$ l. The mixtures were incubated with 100  $\mu$ l of Factor VII-deficient plasma (George King Bio-Medical Inc., Overland Park, KS) and 200  $\mu$ l of thromboplastin C (Dade, Miami, FL; contains rabbit brain thromboplastin and 11.8 mM  $\text{Ca}^{++}$ ). The clotting assay was performed in an automatic coagulation timer (MLA Electra 800, Medical Laboratory Automation Inc., Pleasantville, NY), and clotting times were converted to units of Factor VII activity using a standard curve constructed with 1:5 to 1:640 dilutions of normal pooled human plasma (assumed to contain one unit per ml Factor VII activity; prepared by pooling citrated serum from healthy donors). Using this assay the preparations of modified Factor VII exhibited no detectable coagulant activity. Table 2 shows results of the assay in terms of clotting times for control (untransfected) BHK cell-conditioned media (+/- vitamin K), wild-type Factor VII and two isolates of cells expressing the modified Factor VII. Factor VII activity is seen as a reduction in clotting time over control samples.

Table 2

	<u>Sample</u>	<u>Dilution</u>	<u>Clotting Time (sec.)</u>
25	Control +K	1:5	33.1
		1:10	33.4
	Control -K	1:5	34.3
		1:10	33.2
30	Wild-type Factor VII	1:20	19.0
		1:40	21.5
		1:80	23.3
35	Modified Factor VII (#6)	1:1	33.5
	Modified Factor VII (#10)	1:1	32.5

To determine the effect of the modified Factor VII on plasma factor substrates, preparations of modified Factor

VII and recombinant wild-type or native Factor VII are incubated with either Factor X or Factor IX and the activation thereof monitored by clotting assays or polyacrylamide gel electrophoresis.

5

### EXAMPLE III

#### Ability of Modified Factor VII to Bind Tissue Factor

The ability of the modified Factor VII to compete with wild-type Factor VII for tissue factor and inhibit its clotting activity was assessed in a one-step clotting assay in the presence of a limiting amount of tissue factor (thromboplastin).

Clotting times were determined in a one-step assay similar to that described in Example II. A limited amount of tissue factor, a constant amount of wild type Factor VII, and increasing amounts of variant Factor VII were used in the mixing experiments. An inhibition of Factor VII/VIIa procoagulant activity would be seen as an increase in clotting time in assays containing increasing amounts of variant Factor VII.

The amount of Factor VII activity in the test samples was calculated as a percentage of a standard curve that measured Factor VII activity in normal pooled plasma. The standard curve for Factor VII activity was generated using serial dilutions of normal pooled plasma in phosphate buffered solution (PBS) that ranged from 1:5 to 1:640. For this purpose it was assumed that normal plasma contains approximately 500 ng/ml of Factor VII and this was considered to be one unit of activity. A mixture of 100  $\mu$ l Factor VII-deficient plasma, 100  $\mu$ l plasma dilution and 200  $\mu$ l of thromboplastin-C (Dade, Miami, FL.) was used to measure clotting time on a MLA Electra 800 automatic timer. To establish the standard curve, the results were graphed as percentage of activity (1:5 = 100% activity) versus clotting time in seconds.

The assay required that the medium containing the wild type and variant Factor VII be composed of less than one percent serum. The dilutions were made in PBS so that clotting times would fall along the standard curve. A minimum dilution of 1:2 was typical. The final volume was 100  $\mu$ l. Two different human Factor VII Ser<sub>344</sub>  $\rightarrow$  Ala variants, designated clones "#10" and "#6" were tested in the experiments. The results, set forth in the Table below, show that as the amount of Factor VII variant increased, the percent of Factor VIIa activity decreased.

Table 3: Results of mixing assay with Ser<sub>344</sub>  $\rightarrow$  Ala Variants (B4A1 (wild type) medium was used as 100% activity at 10  $\mu$ l/reaction)

Ser344 $\rightarrow$ Ala Clone No.	Variant medium amount	B4A1 medium amount	BHK Control*	Percent FVIIa Activity
#10	10 $\mu$ l	10 $\mu$ l	0	70
#10	20 $\mu$ l	10 $\mu$ l	0	51
#10	30 $\mu$ l	10 $\mu$ l	0	43
#10	40 $\mu$ l	10 $\mu$ l	0	34
#10	50 $\mu$ l	10 $\mu$ l	0	28
#10 (-K) <sup>§</sup>	20 $\mu$ l	10 $\mu$ l	0	78
<hr/>				
#6	10 $\mu$ l	10 $\mu$ l	0	74
#6	20 $\mu$ l	10 $\mu$ l	0	56
#6	30 $\mu$ l	10 $\mu$ l	0	46
#6	40 $\mu$ l	10 $\mu$ l	0	41
#6	50 $\mu$ l	10 $\mu$ l	0	32
#6 (-K)	20 $\mu$ l	10 $\mu$ l	0	85
BHK control	0	10 $\mu$ l	20 $\mu$ l	91
BHK control (-K)	0	10 $\mu$ l	20 $\mu$ l	107

\* Untransfected conditioned medium

§ For expression of the Factor VII variant, cells were grown in the presence of vitamin K, except where noted "(-K)".

These experiments showed that variants of Factor VII having a Ser<sub>344</sub>  $\rightarrow$  Ala substitution competed with native Factor VII in a dose dependent fashion and inhibited the procoagulant activity of native Factor VII/VIIa. It can thus be concluded that Ser<sub>344</sub>  $\rightarrow$  Ala variant human Factor VII competes with native human Factor VIIa and consequently inhibits activation of Factor X and/or IX in human plasma.

EXAMPLE IVReaction of Factor VII with PPACK

Recombinant Factor VII was produced in transfected baby hamster kidney cells. The protein was purified and activated as disclosed by Thim et al. (Biochemistry 27: 7785-7793, 1988), Brinkous et al. (Proc. Natl. Acad. Sci. USA 86: 1382-1386, 1989) and Bjoern and Thim (Res. Discl. No. 269, 564, 1986), which are incorporated herein by reference. The cell culture medium was recovered, filtered and diluted to reduce sale concentration. The diluted medium was then fractionated by anion exchange chromatography using an elution buffer containing  $\text{CaCl}_2$ . The Factor VII fraction was recovered and further purified by immunochromatography using a calcium-dependent anti-Factor VII monoclonal antibody. Additional purification was carried out using two anion exchange chromatography steps wherein Factor VII was eluted using  $\text{CaCl}_2$  and  $\text{NaCl}$ , respectively. Factor Vlla was recovered in the final eluate.

Recombinant Factor Vlla ( $1 \mu\text{M}$ ) in 50 mM Tris-HCl, 100 mM NaCl, 5 mM  $\text{CaCl}_2$ , ph 7.4 was incubated with 20  $\mu\text{M}$  PPack (D-Phenylalanyl-Prolyl-Arginyl Chloromethyl Ketone; Calbiochem, La Jolla, CA) for 5, 20 and 60 minutes. Buffer containing the chromogenic substrate S2288 (H-D-Isoleucine-L-Prolyl-L-Arginine p-nitroanilide; Kabi Vitrum AB, Molndal, Sweden) was then added to obtain a 2.5 fold dilution and a final concentration of 0.3 mM S2288. The generation of p-nitroaniline was measured and compared to results using untreated Factor Vlla as a control. The results indicated that Factor Vlla is fully inactivated after about 60 minutes under these reaction conditions.

EXAMPLE VGeneration of DEGR-Factor VIIa

Recombinant human Factor VIIa was prepared as described in Example IV. Recombinant human Factor VIIa, in 10 mM glycine buffer, pH 8.0, 10 mM  $\text{CaCl}_2$ , 50 mM NaCl, was diluted to a concentration of 1.5 mg/ml. A 10-fold molar

excess of Dansyl-L-Glu-Gly-Arg-Chloromethyl Ketone, DEGRck, (Calbiochem, La Jolla, CA 92037) which had been dissolved with distilled H<sub>2</sub>O was added to the Factor VIIa. After a 2 hr incubation at 37°C, a second 10-fold molar excess of DEGRck was added to the mixture and incubated for an additional 2 hr at 37°C. A third 10-fold molar excess of DEGRck was added to the Factor VIIa and incubated for approximately 16 hours at 4°C. The DEGR-Factor VIIa sample was then extensively dialyzed at 4°C against Tris buffered saline (0.05 M Tris-HCl, 0.1 M NaCl, pH 7.5) to remove any free DEGRck.

The final DEGR-Factor VIIa mixture was tested for the presence of free DEGRck in a Factor Xa chromogenic substrate assay. The DEGR-Factor VIIa mixture was added to purified human Factor Xa along with the chromogenic substrate S-2222. This substrate is cleaved specifically by Factor Xa and not by Factor VIIa. Unbound DEGRck in the mixture is able to bind to the Factor Xa and thereby inhibit the chromogenic activity of the Factor Xa. Spiking free DEGR-ck into a Factor Xa mixture generated a standard curve to measure the level of free DEGRck in solution versus the inhibition of Factor Xa chromogenic activity. Analysis of the DEGR-Factor VIIa mixture showed that the ratio of free DEGRck:DEGR-Factor VIIa was less than 0.5% following extensive dialysis, thereby ensuring that the inhibition observed by DEGR-Factor VIIa in the various assay systems described below was not due to the presence of free DEGRck.

#### Example VI

##### Factor Xa generation on rat smooth muscle cells

Vascular smooth muscle cells were analyzed for the presence of cell-surface tissue factor by measuring the ability of the cells to stimulate the conversion of Factor X to Factor Xa using a chromogenic substrate that is specific for Factor Xa.

Rat vascular smooth muscle cells (Clowes et al., J. Clin. Invest. 93:644-651 (1994)) were plated into 96-well

culture dishes (American Scientific Products, Chicago, IL.) at 8,000 cells per well in growth media (Table 4).

Table 4

5 500 ml Dulbecco's Modified Eagle's Medium (DMEM) (GIBCO-BRL, Gaithersburg, MD.)  
10% fetal calf serum (Hyclone, Logan, UT.)  
1mM sodium pyruvate (Irvine, Santa Ana, CA.)  
10 0.29 mg/ml L-glutamine (Hazelton, Lenexa, KS.)  
1x PSN; (100X is 5 mg/ml penicillin, 5 mg/ml streptomycin,  
10 mg/ml neomycin) (GIBCO-BRL, Gaithersburg, MD.)

After a 48 hour incubation at 37°C the medium was  
15 changed to serum free medium (Table 5).

Table 5

250 ml Dulbecco's Modified Eagle's Medium (DMEM)  
250 ml Ham's F-12 Medium (Fred Hutchinson Cancer Research  
20 Center, Seattle, WA)  
1mM sodium pyruvate  
.29 mg/ml L-glutamine  
20 µM transferrin (JRH, Lenexa, KS.)  
5 µM insulin (GIBCO-BRL)  
25 16 ng selenium (Aldrich, Milwaukee, WI.)  
1 mg/ml bovine serum albumin (Sigma, St. Louis, MO)

The cells were incubated 72 hours at 37°C. After  
30 incubation, either PDGF-BB (10 ng/ml) or 10% fetal calf serum  
was added to the cells to stimulate tissue factor expression  
(Taubman et al., J. Clin. Invest. 91:547-552, 1993). A  
parallel set of cells received neither PDGF nor serum to  
monitor for intrinsic activity of unstimulated cells. After  
35 a 6 hour incubation, recombinant human Factor VIIa was added  
to the cells at a final concentration of 10 nM. One set of  
cells did not have Factor VIIa added as a negative control.  
The cells were incubated for 2 hours at 37°C and washed with  
HEPES buffer (10 mM HEPES, 137 mM NaCl, 4 mM KCl, 5 mM CaCl<sub>2</sub>,  
40 11 mM glucose, 0.1% BSA). After washing, cells were incubated  
for 5 min with 50 µl per well of 200 nM plasma-purified human  
Factor X in a Tris-buffered saline supplemented with 5 mM  
CaCl<sub>2</sub>. Twenty-five microliters of 0.5 M EDTA and 25 µl of an  
800 µM solution of S-2222 chromogenic substrate (Kabi

Pharmacia, Franklin, OH) were added to each well. The plates were incubated for 40 min at room temperature, then analyzed at 405 nm using a THERMO MAX Microplate Reader (Molecular Devices, Menlo Park, CA).

5           Table 6 shows an increase in absorbance for the Factor VIIa treated wells as compared to the control wells (no Factor VIIa added). The increase in absorbance is a direct measurement of the level of Factor Xa generated in the wells and its subsequent cleavage of the chromogenic substrate,  
10           releasing the chromophore. The data also demonstrate that the level of chromogenic activity in cells pretreated with either PDGF-BB or 10% fetal calf serum was higher than unstimulated cells.

15

Table 6

Test Sample	OD <sub>405</sub>
Control	.043
Intrinsic	.247
PDGF-BB	.360
20       10% FCS	.342

          These results clearly show there is a Factor VIIa-dependent activation of Factor X to Factor Xa on the cell surface of rat vascular smooth muscle cells.

25

#### Example VII

##### Inhibition of cell-surface chromogenic activity by DEGR-Factor VIIa.

          Rat vascular smooth muscle cells were plated into  
30       96-well culture dishes as described above. The cells were cultured for 72 hours in serum free media as described above and treated with the addition of 10% fetal calf serum for 6 hours to stimulate tissue factor expression. After  
          stimulation buffer only (control), 10 nM Factor VIIa, or 10 nM  
35       Factor VIIa + 100 nM DEGR-Factor VIIa was added to each well. The cells were incubated for 2 hours at 37°C, then washed with HEPES buffer. After washing, the cells were incubated for 5

minutes with 50  $\mu$ l per well of 200 nM Factor X in Tris-buffered saline supplemented with 5 mM  $\text{CaCl}_2$ . Twenty-five microliters of 0.5 M EDTA and 25  $\mu$ l of S-2222 (800  $\mu$ M) chromogenic substrate (Kabi Pharmacia) were added to each well. The cells were incubated at room temperature for 40 minutes. Chromogenic activity was analyzed at 405 nm as described above.

Table 7 shows stimulation of chromogenic activity in the wells treated with Factor VIIa only, and inhibition of stimulation when DEGR-Factor VIIa was coincubated with the Factor VIIa. These results demonstrate that DEGR-Factor VIIa acts as a competitive antagonist for Factor VIIa binding, thereby inhibiting the activation of Factor X to Factor Xa and the subsequent cleavage of the S-2222 chromogen.

Table 7

Test Sample	OD <sub>405</sub>
Control	.035
Factor VIIa	.342
Factor VIIa + DEGR-Factor VIIa	.073

#### Example VIII

##### Dose dependent inhibition by DEGR-Factor VIIa of cell surface chromogenic activity on rat smooth muscle cells.

Rat vascular smooth muscle cells were plated into 96-well culture dishes at 4,000 cells per well in growth medium supplemented with 1% fetal calf serum (as in Table 4 without 10% fetal calf serum). After 5 days the medium was removed, and either increasing concentrations of Factor VIIa alone or 10 nM Factor VIIa with increasing concentrations of DEGR-Factor VIIa were added to the cells. The cells were incubated with the Factor VII mixtures for 2 hours at 37°C. After incubation, the cells were washed and incubated with 50  $\mu$ l of 200 nM Factor X in tris buffered saline for 5 minutes at room temperature. Each well had 25  $\mu$ l of 0.5 M EDTA and 25  $\mu$ l

of 800  $\mu$ M S-2222 (Kabi Pharmacia) added to it, and the plates were incubated for 40 minutes at room temperature.

Chromogenic activity was analyzed at 405 nm in a microplate reader as described above.

5                   Table 8 shows a dose-dependent increase in chromogenic activity with increasing amounts of Factor VIIa added to the wells. When the mixture of DEGR-Factor VIIa with 100 nM Factor VIIa was added to the cells (Table 9) there was a dose dependent inhibition in chromogenic activity. A 1:1  
10 molar ratio of DEGR-Factor VIIa:Factor VIIa inhibited approximately 95% of the chromogenic activity. These data suggest that DEGR-Factor VIIa has a significantly higher affinity for cell-surface tissue factor than native Factor VIIa. If DEGR-Factor VIIa and Factor VIIa had equal affinity  
15 for binding tissue factor then the level of inhibition observed when the two molecules were added to the cells in an equal molar ratio would not have been as high.

Table 8

20	Factor VIIa Conc. (nM)	OD <sub>405</sub>
	.10	.005
	.39	.025
	1.56	.058
25	6.25	.111
	25.00	.154
	100.00	.208

30

Table 9 shows the dose dependent inhibition of Factor Xa chromogenic activity on rat smooth muscle cells by DEGR-Factor VIIa. Increasing concentrations of DEGR-Factor VIIa were coincubated with 100 nM Factor VIIa, and the Factor  
35 Xa chromogenic activity determined using chromogenic substrate S-2222.

Table 9

	DEGR-Factor VIIa Conc. (nM)	OD <sub>405</sub>
5	.00	.208
	.39	.176
	1.56	.116
	6.25	.073
	25.00	.026
10	100.00	.014

15

Example IXInhibition of Factor Xa generation byDEGR-Factor VIIa in a soluble tissue factor assay.

The conversion of Factor X to Factor Xa using purified recombinant soluble tissue factor was established using a chromogenic assay. Tissue factor was expressed and purified from Saccharomyces cerevisiae (Shigematsu et al., J. Biol. Chem. 267:21329-21337, 1992). Soluble tissue factor was purified and characterized by Dr. Walt Kisiel (University of New Mexico, Albuquerque, NM). A reaction mixture containing 65.9  $\mu$ l of soluble tissue factor (2.2  $\mu$ M), 29.0  $\mu$ l of PCPS (1 mM, Sigma, St. Louis, MO), 29.5  $\mu$ l human Factor X (4.1  $\mu$ M), 2.77 ml Hank's buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 2.7 mM KCl, 5 mM CaCl<sub>2</sub>, 0.1% BSA) was prepared. Forty microliter of tissue factor/Factor X mixture, 25  $\mu$ l Factor VIIa diluted with TBS and 25  $\mu$ l of DEGR-Factor VIIa diluted with TBS were added to each well of a 96-well microtiter plate. A control using 40  $\mu$ l of tissue factor/Factor X mixture; 25  $\mu$ l Factor VIIa diluted with TBS, and 25  $\mu$ l of TBS only was included. Ten microliters of S-2222 (4 mM) chromogenic substrate was added to the reaction mixture in the wells and incubated at room temperature for 2-10 minutes. Results were analyzed at 405 nm in a microplate reader as described above.

Determination of a standard curve for Factor VIIa activation of Factor X was made using increasing concentrations of Factor VIIa added in the absence of DEGR-Factor VIIa. The results, presented in Table 10, show that

40

there is a dose-dependent increase in chromogenic activity with increasing amounts of Factor VIIa added to the reaction mixture. The simultaneous addition of varying amounts of DEGR-Factor VIIa and 100 nM Factor VIIa led to a dose dependent decrease in chromogenic activity (Table 11). These data demonstrate that DEGR-Factor VIIa acts as a competitive antagonist for native Factor VIIa binding to soluble tissue factor, and thereby inhibits the generation of Factor Xa as measured by the decrease in chromogenic activity towards the chromogenic substrate S-2222.

Table 10

Stimulation of Factor Xa chromogenic activity with increasing concentrations of Factor VIIa added to soluble tissue factor. Changes in optical density were measured using chromogenic substrate S-2222.

	Factor VIIa Conc (nM)	OD <sub>405</sub>
20	.78	.168
	1.56	.288
	3.12	.478
	6.25	.694
	12.50	.764
25	25.00	.790
	50.00	.738
	100.00	.770

Table 11

Inhibition of Factor Xa chromogenic activity by the addition of DEGR-Factor VIIa to soluble tissue factor in the presence of native Factor VIIa is measured. Changes in optical density were measured using the chromogenic substrate S-2222.

	DEGR-Factor VIIa Conc. (nM)	OD <sub>405</sub>
	0.810	
	50.750	
40	100.609	
	200.296	
	400.167	
	800.083	
45	1600.055	

Example XInhibition of coagulation by DEGR-Factor VIIa.

Standard clotting assays to monitor the effect of DEGR-Factor VIIa on clotting time were prepared as follows: 100  $\mu$ l of normal baboon plasma, collected with sodium citrate as anticoagulant, was added to 100  $\mu$ l of varying concentrations of DEGR-Factor VIIa diluted in TBS (20 mM Tris, pH 7.4, 150 mM NaCl). The samples were mixed and briefly incubated at 37°C. The samples were added to an Electra 800 Automatic Coagulation Timer (Medical Laboratories Automation, Pleasantville, NY). After incubation, 200  $\mu$ l of a tissue factor preparation containing 25 mM  $\text{CaCl}_2$  was added to the DEGR-Factor VIIa preparations. A tissue factor preparation was made as a saline extract of baboon brain that from freshly frozen brain tissue and characterized for its ability to initiate coagulation in baboon plasma. A concentration of tissue factor that gave a clotting time of about 40 seconds was selected.

The data, presented in Table 12, demonstrates a dose-dependent increase in clotting time due to the addition of DEGR-Factor VIIa. A dose as low as 1  $\mu$ g/ml of DEGR-Factor VIIa in plasma resulted in a significant increase in clotting time.

Table 12

Dose dependent increase in clotting time due to DEGR-Factor VIIa.

<u>DEGR-Factor VIIa</u> <u>(<math>\mu</math>g/ml plasma)</u>	<u>Clotting time</u> <u>(seconds)</u>
0	40.7
0.5	46.2
1.0	50.8
2.5	64.5
5.0	108.1
10.0	158.4

Example XI  
Inhibition of platelet accumulation  
with DEGR-Factor VIIa.

5        DEGR-Factor VIIa was analyzed for its ability to  
inhibit platelet accumulation at sites of arterial thrombosis  
due to mechanical injury in non-human primates. A model of  
aortic endarterectomy was utilized in baboons, essentially as  
described by Lumsden et al. (Blood 81:1762-1770, 1993). A  
10       section of baboon aorta 1-2 cm in length was removed, inverted  
and scraped to remove the intima of the artery and  
approximately 50% of the media. The artery was reverted back  
to its correct orientation, cannulated on both ends and placed  
into an extracorporeal shunt in a baboon, thereby exposing the  
mechanically injured artery to baboon blood via the shunt.  
15       Just prior to opening of the shunt to the circulating blood,  
<sup>111</sup>In-labeled autologous platelets were injected intravenously  
into the animal. The level of platelet accumulation at the  
site of the injured artery was determined by real-time gamma  
camera imaging.

20       Evaluation of DEGR-Factor VIIa for inhibition of  
platelet accumulation was done using bolus injections of DEGR-  
Factor VIIa or saline control and were given just prior to the  
opening of the shunt. The injured arteries were measured  
continuously for 60 minutes. A dose of 0.005 mg/kg of DEGR-  
25       Factor VIIa inhibited platelet accumulation. At a 1.0 mg/kg  
bolus injection, approximately 90% of platelet accumulation  
was inhibited at 1 hour post drug administration.

30       These data show that inhibition of tissue factor  
with DEGR-Factor VIIa can significantly inhibit the  
development of platelet-rich thrombi in a nonhuman primate  
model of acute vascular injury.

35       It is evident from the foregoing that compositions  
of Factor VII or VII having modified catalytic sites are  
provided which are able to bind tissue factor yet are  
substantially unable to activate Factors X and IX. As  
modified Factor VII acts specifically to interrupt the

clotting cascade without degrading or consuming clotting factors, it can be expected that administration of modified Factor VII preparations will be accompanied by fewer undesirable side effects than experienced with current therapies. Further, the modified Factor VII described herein may readily be produced by recombinant means. Thus efficacy, convenience and economics of lower dosages and less frequent administration, and a relative lack of toxicity are among the advantages conferred by the compositions of the present invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT:
  - (A) NAME: ZymoGenetics, Inc. et al.
  - (B) STREET: 4225 Roosevelt Way N.E.
  - (C) CITY: Seattle
  - (D) STATE: Washington
  - (E) COUNTRY: United States of America
  - (F) POSTAL CODE (ZIP): 98105
  - (G) TELEPHONE: (206)547-8080
  - (H) TELEFAX:
  - (I) TELEX:
- (ii) TITLE OF INVENTION: Modified Factor VII
- (iii) NUMBER OF SEQUENCES: 4
- (iv) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (v) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE: 23-MAY-1994
  - (C) CLASSIFICATION:
- (vi) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 08/065,725
  - (B) FILING DATE: 21-MAY-1993
- (vi) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 07/662,920
  - (B) FILING DATE: 28-FEB-1991
- (vii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Parmelee, Steven W.
  - (B) REGISTRATION NUMBER: 31,990
  - (C) REFERENCE/DOCKET NUMBER: 13952-8-1PC
- (viii) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 206-467-9600
  - (B) TELEFAX: 415-543-5043

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2422 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: N
- (iv) ANTI-SENSE: N
- (ix) FEATURE:
  - (A) NAME/KEY: CDS
  - (B) LOCATION: 28..1420
  - (D) OTHER INFORMATION: /codon\_start= 28  
/product= "Factor VII"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCTCCCCACA ATACAGGGGC AGCACTGCAG AGATTTCATC															ATG Met -38	GTC Val	TCC Ser	CAG Gln -35	GCC Ala	55
CTC Leu	AGG Arg	CTC Leu	CTC Leu -30	TGC Cys	CTT Leu	CTG Leu	CTT Leu	GGG Gly -25	CTT Leu	CAG Gln	GGC Gly	TGC Cys	CTG Leu -20	GCT Ala	GCA Ala	103				
GTC Val	TTC Phe	GTA Val -15	ACC Thr	CAG Gln	GAG Glu	GAA Glu	GCC Ala -10	CAC His	GGC Gly	GTC Val	CTG Leu	CAC His -5	CGG Arg	CGC Arg	CGG Arg	151				
CGC Arg	GCC Ala 1	AAC Asn	GCG Ala	TTC Phe	CTG Leu 5	GAG Glu	GAG Glu	CTG Leu	CGG Arg	CCG Pro 10	GGC Gly	TCC Ser	CTG Leu	GAG Glu	AGG Arg 15	199				
GAG Glu	TGC Cys	AAG Lys	GAG Glu 20	GAG Gln 20	CAG Gln	TGC Cys	TCC Ser	TTC Phe	GAG Glu 25	GAG Glu	GCC Ala	CGG Arg	GAG Glu 30	ATC Ile 30	TTC Phe	247				
AAG Lys	GAC Asp	GCG Ala	GAG Glu 35	AGG Arg	ACG Thr	AAG Lys	CTG Leu	TTC Phe 40	TGG Trp	ATT Ile	TCT Ser	TAC Tyr	AGT Ser 45	GAT Asp	GGG Gly	295				
GAC Asp	CAG Gln	TGT Cys 50	GCC Ala	TCA Ser	AGT Ser	CCA Pro	TGC Cys 55	CAG Gln	AAT Asn	GGG Gly	GGC Gly	TCC Ser 60	TGC Cys	AAG Lys	GAC Asp	343				
CAG Gln	CTC Leu 65	CAG Gln	TCC Ser	TAT Tyr	ATC Ile	TGC Cys 70	TTC Phe	TGC Cys	CTC Leu	CCT Pro	GCC Ala 75	TTC Phe	GAG Glu	GGC Gly	CGG Arg	391				
AAC Asn 80	TGT Cys	GAG Glu	ACG Thr	CAC His	AAG Lys 85	GAT Asp	GAC Asp	CAG Gln	CTG Leu	ATC Ile 90	TGT Cys	GTG Val	AAC Asn	GAG Glu	AAC Asn 95	439				
GGC Gly	GGC Gly	TGT Cys	GAG Glu 100	CAG Gln 100	TAC Tyr	TGC Cys	AGT Ser	GAC Asp	CAC His 105	ACG Thr	GGC Gly	ACC Thr	AAG Lys	CGC Arg 110	TCC Ser	487				
TGT Cys	CGG Arg	TGC Cys	CAC His 115	GAG Glu	GGG Gly	TAC Tyr	TCT Ser	CTG Leu 120	CTG Leu	GCA Ala	GAC Asp	GGG Gly	GTG Val 125	TCC Ser	TGC Cys	535				
ACA Thr	CCC Pro	ACA Thr 130	GTT Val	GAA Glu	TAT Tyr	CCA Pro	TGT Cys 135	GGA Gly	AAA Lys	ATA Ile	CCT Pro	ATT Ile 140	CTA Leu	GAA Glu	AAA Lys	583				
AGA Arg	AAT Asn 145	GCC Ala	AGC Ser	AAA Lys	CCC Pro	CAA Gln 150	GGC Gly	CGA Arg	ATT Ile	GTG Val	GGG Gly 155	GGC Gly	AAG Lys	GTG Val	TGC Cys	631				
CCC Pro 160	AAA Lys	GGG Gly	GAG Glu	TGT Cys	CCA Pro 165	TGG Trp	CAG Gln	GTC Val	CTG Leu	TTG Leu 170	TTG Leu	GTG Val	AAT Asn	GGA Gly	GCT Ala 175	679				
CAG Gln	TTG Leu	TGT Cys	GGG Gly 180	GGG Gly	ACC Thr	CTG Leu	ATC Ile	AAC Asn	ACC Thr 185	ATC Ile	TGG Trp	GTG Val	GTC Val	TCC Ser 190	GCG Ala	727				
GCC Ala	CAC His	TGT Cys	TTC Phe 195	GAC Asp	AAA Lys	ATC Ile	AAG Lys	AAC Asn 200	TGG Trp	AGG Arg	AAC Asn	CTG Leu	ATC Ile 205	GCG Ala	GTG Val	775				
CTG Leu	GGC Gly 210	GAG Glu 210	CAC His	GAC Asp	CTC Leu	AGC Ser	GAG Glu 215	CAC His	GAC Asp	GGG Gly	GAT Asp 220	GAG Glu 220	CAG Gln	AGC Ser	CGG Arg	823				

CGG	GTG	GCG	CAG	GTC	ATC	CCC	AGC	ACG	TAC	GTC	CCG	GGC	ACC	ACC		871
Arg	Val	Ala	Gln	Val	Ile	Ile	Pro	Ser	Thr	Tyr	Val	Pro	Gly	Thr	Thr	
225						230					235					
AAC	CAC	GAC	ATC	GCG	CTG	CTC	CGC	CTG	CAC	CAG	CCC	GTG	GTC	CTC	ACT	919
Asn	His	Asp	Ile	Ala	Leu	Leu	Arg	Leu	His	Gln	Pro	Val	Val	Leu	Thr	
240					245					250					255	
GAC	CAT	GTG	GTG	CCC	CTC	TGC	CTG	CCC	GAA	CGG	ACG	TTC	TCT	GAG	AGG	967
Asp	His	Val	Val	Pro	Leu	Cys	Leu	Pro	Glu	Arg	Thr	Phe	Ser	Glu	Arg	
				260					265					270		
ACG	CTG	GCC	TTC	GTG	CGC	TTC	TCA	TTG	GTC	AGC	GGC	TGG	GGC	CAG	CTG	1015
Thr	Leu	Ala	Phe	Val	Arg	Phe	Ser	Leu	Val	Ser	Gly	Trp	Gly	Gln	Leu	
			275					280					285			
CTG	GAC	CGT	GGC	GCC	ACG	GCC	CTG	GAG	CTC	ATG	GTC	CTC	AAC	GTG	CCC	1063
Leu	Asp	Arg	Gly	Ala	Thr	Ala	Leu	Glu	Leu	Met	Val	Leu	Asn	Val	Pro	
		290					295					300				
CGG	CTG	ATG	ACC	CAG	GAC	TGC	CTG	CAG	CAG	TCA	CGG	AAG	GTG	GGA	GAC	1111
Arg	Leu	Met	Thr	Gln	Asp	Cys	Leu	Gln	Gln	Ser	Arg	Lys	Val	Gly	Asp	
	305					310					315					
TCC	CCA	AAT	ATC	ACG	GAG	TAC	ATG	TTC	TGT	GCC	GGC	TAC	TCG	GAT	GGC	1159
Ser	Pro	Asn	Ile	Thr	Glu	Tyr	Met	Phe	Cys	Ala	Gly	Tyr	Ser	Asp	Gly	
320					325					330					335	
AGC	AAG	GAC	TCC	TGC	AAG	GGG	GAC	AGT	GGA	GGC	CCA	CAT	GCC	ACC	CAC	1207
Ser	Lys	Asp	Ser	Cys	Lys	Gly	Asp	Ser	Gly	Gly	Pro	His	Ala	Thr	His	
				340					345					350		
TAC	CGG	GGC	ACG	TGG	TAC	CTG	ACG	GGC	ATC	GTC	AGC	TGG	GGC	CAG	GGC	1255
Tyr	Arg	Gly	Thr	Trp	Tyr	Leu	Thr	Gly	Ile	Val	Ser	Trp	Gly	Gln	Gly	
			355					360					365			
TGC	GCA	ACC	GTG	GGC	CAC	TTT	GGG	GTG	TAC	ACC	AGG	GTC	TCC	CAG	TAC	1303
Cys	Ala	Thr	Val	Gly	His	Phe	Gly	Val	Tyr	Thr	Arg	Val	Ser	Gln	Tyr	
		370					375					380				
ATC	GAG	TGG	CTG	CAA	AAG	CTC	ATG	CGC	TCA	GAG	CCA	CGC	CCA	GGA	GTC	1351
Ile	Glu	Trp	Leu	Gln	Lys	Leu	Met	Arg	Ser	Glu	Pro	Arg	Pro	Gly	Val	
	385					390					395					
CTC	CTG	CGA	GCC	CCA	TTT	CCC	TAG	C	CCAGCAGCCCC	TGGCCTGTGG						1396
Leu	Leu	Arg	Ala	Pro	Phe	Pro										
400					405											
AGAGAAAGCC	AAGGCTGCGT	CGAACTGTCC	TGGCACCAAA	TCCCATATAT	TCTTCTGCAG											1456
TTAATGGGGT	AGAGGAGGGC	ATGGGAGGGA	GGGAGAGGTG	GGGAGGGAGA	CAGAGACAGA											1516
AACAGAGAGA	GACAGAGACA	GAGAGAGACT	GAGGGAGAGA	CTCTGAGGAC	ATGGAGAGAG											1576
ACTCAAAGAG	ACTCCAAGAT	TCAAAGAGAC	TAATAGAGAC	ACAG												

GATATGCACA CACATGGATG AGCACACACA CACCAAGTGC GCACACACAC CGATGTACAC 2116  
 ACACAGATGC ACACACAGAT GCACACACAC CGATGCTGAC TCCATGTGTG CTGTCCTCTG 2176  
 AAGGCGGTTG TTTAGCTCTC ACTTTTCTGG TTCTTATCCA TTATCATCTT CACTTCAGAC 2236  
 AATTCAGAAAG CATCACCATG CATGGTGGCG AATGCCCCCA AACTCTCCCC CAAATGTATT 2296  
 TCTCCCTTCG CTGGGTGCCG GGCTGCACAG ACTATTCCCC ACCTGCTTCC CAGCTTCACA 2356  
 ATAAACGGCT GCGTCTCCTC CGCACACCTG TGGTGCCTGC CACCCAAAAA AAAAAAAAAA 2416  
 AAAAAA 2422

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 444 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein.

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Val Ser Gln Ala Leu Arg Leu Leu Trp Leu Leu Leu Gly Leu Gln  
 -38 -35 -30 -25  
 Gly Cys Leu Ala Ala Val Phe Val Thr Gln Glu Glu Ala His Gly Val  
 -20 -15 -10  
 Leu His Arg Arg Arg Arg Ala Asn Ala Phe Leu Glu Glu Leu Arg Pro  
 -5 1 5 10  
 Gly Ser Leu Glu Arg Glu Cys Lys Glu Glu Gln Cys Ser Phe Glu Glu  
 15 20 25  
 Ala Arg Glu Ile Phe Lys Asp Ala Glu Arg Thr Lys Leu Phe Trp Ile  
 30 35 40  
 Ser Tyr Ser Asp Gly Asp Gln Cys Ala Ser Ser Pro Cys Gln Asn Gly  
 45 50 55  
 Gly Ser Cys Lys Asp Gln Leu Gln Ser Tyr Ile Cys Phe Cys Leu Pro  
 60 65 70  
 Ala Phe Glu Gly Arg Asn Cys Glu Thr His Lys Asp Asp Gln Leu Ile  
 75 80 85 90  
 Cys Val Asn Glu Asn Gly Gly Cys Glu Gln Tyr Cys Ser Asp His Thr  
 95 100 105  
 Gly Thr Lys Arg Ser Cys Arg Cys His Glu Gly Tyr Ser Leu Leu Ala  
 110 115 120  
 Asp Gly Val Ser Cys Thr Pro Thr Val Glu Tyr Pro Cys Gly Lys Ile  
 125 130 135  
 Pro Ile Leu Glu Lys Arg Asn Ala Ser Lys Pro Gln Gly Arg Ile Val  
 140 145 150

Gly	Gly	Lys	Val	Cys	Pro	Lys	Gly	Glu	Cys	Pro	Trp	Gln	Val	Leu	Leu	155	160	165	170
Leu	Val	Asn	Gly	Ala	Gln	Leu	Cys	Gly	Gly	Thr	Leu	Ile	Asn	Thr	Ile	175	180	185	
Trp	Val	Val	Ser	Ala	Ala	His	Cys	Phe	Asp	Lys	Ile	Lys	Asn	Trp	Arg	190	195	200	
Asn	Leu	Ile	Ala	Val	Leu	Gly	Glu	His	Asp	Leu	Ser	Glu	His	Asp	Gly	205	210	215	
Asp	Glu	Gln	Ser	Arg	Arg	Val	Ala	Gln	Val	Ile	Ile	Pro	Ser	Thr	Tyr	220	225	230	
Val	Pro	Gly	Thr	Thr	Asn	His	Asp	Ile	Ala	Leu	Leu	Arg	Leu	His	Gln	235	240	245	250
Pro	Val	Val	Leu	Thr	Asp	His	Val	Val	Pro	Leu	Cys	Leu	Pro	Glu	Arg	255	260	265	
Thr	Phe	Ser	Glu	Arg	Thr	Leu	Ala	Phe	Val	Arg	Phe	Ser	Leu	Val	Ser	270	275	280	
Gly	Trp	Gly	Gln	Leu	Leu	Asp	Arg	Gly	Ala	Thr	Ala	Leu	Glu	Leu	Met	285	290	295	
Val	Leu	Asn	Val	Pro	Arg	Leu	Met	Thr	Gln	Asp	Cys	Leu	Gln	Gln	Ser	300	305	310	
Arg	Lys	Val	Gly	Asp	Ser	Pro	Asn	Ile	Thr	Glu	Tyr	Met	Phe	Cys	Ala	315	320	325	330
Gly	Tyr	Ser	Asp	Gly	Ser	Lys	Asp	Ser	Cys	Lys	Gly	Asp	Ser	Gly	Gly	335	340	345	
Pro	His	Ala	Thr	His	Tyr	Arg	Gly	Thr	Trp	Tyr	Leu	Thr	Gly	Ile	Val	350	355	360	
Ser	Trp	Gly	Gln	Gly	Cys	Ala	Thr	Val	Gly	His	Phe	Gly	Val	Tyr	Thr	365	370	375	
Arg	Val	Ser	Gln	Tyr	Ile	Glu	Trp	Leu	Gln	Lys	Leu	Met	Arg	Ser	Glu	380	385	390	
Pro	Arg	Pro	Gly	Val	Leu	Leu	Arg	Ala	Pro	Phe	Pro	395	400	405					

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGGGCCTCCG GCGTCCCCCT T 21

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCCCAGTCAC GACGT 15

WHAT IS CLAIMED IS:

1. A method for inhibiting tissue factor activity in a patient comprising administering to the patient a therapeutically effective dose of a composition comprising Factor VII having at least one modification in its catalytic center, which modification substantially inhibits the ability of the modified Factor VII to activate plasma Factor X or IX.

2. A method according to claim 1, wherein the modification comprises reaction of the Factor VII with a serine protease inhibitor.

3. A method according to claim 2, wherein the protease inhibitor is an organophosphor compound, a sulfanyl fluoride, a peptide halomethyl ketone, or an azapeptide.

4. A method according to claim 3, wherein the protease inhibitor is a peptide halomethyl ketone selected from D-Phe-Pro-Arg chloromethyl ketone or Dansyl-Glu-Gly-Arg chloromethyl ketone.

5. A method according to claim 1, wherein the Factor VII modification comprises at least one amino acid substitution, insertion, or deletion in a catalytic triad of Ser, Asp, and His.

6. A method for inhibiting vascular restenosis in a patient comprising administering to the patient a therapeutically effective dose of a composition comprising Factor VII having at least one modification in its catalytic center, which modification substantially inhibits the ability of the modified Factor VII to activate plasma Factor X or IX.

7. A method according to claim 6, wherein the modification comprises reaction of the Factor VII with a serine protease inhibitor.

8. A method according to claim 7, wherein the protease inhibitor is an organophosphor compound, a sulfanyl fluoride, a peptide halomethyl ketone, or an azapeptide.

5 9. A method according to claim 8, wherein the protease inhibitor is a peptide halomethyl ketone selected from D-Phe-Pro-Arg chloromethyl ketone or Dansyl-Glu-Gly-Arg chloromethyl ketone.

10 10. A method for inhibiting platelet deposition in a patient comprising administering to the patient a therapeutically effective dose of a composition comprising Factor VII having at least one modification in its catalytic center, which modification substantially inhibits the ability  
15 of the modified Factor VII to activate plasma Factor X or IX.

11. A method according to claim 10, wherein the modification comprises reaction of the Factor VII with a serine protease inhibitor.

20 12. A method according to claim 10, wherein the protease inhibitor is an organophosphor compound, a sulfanyl fluoride, a peptide halomethyl ketone, or an azapeptide.

25 13. A method according to claim 12, wherein the protease inhibitor is a peptide halomethyl ketone selected from D-Phe-Pro-Arg chloromethyl ketone or Dansyl-Glu-Gly-Arg chloromethyl ketone.

30 14. A method according to claim 10, wherein the Factor VII modification comprises at least one amino acid substitution, insertion, or deletion in a catalytic triad of Ser, Asp, and His.

35 15. Use of a composition of a pharmacologically acceptable Factor VII having at least one modification in its catalytic center, which modification substantially inhibits the ability of the modified Factor VII to activate plasma


Factor X or IX, for the treatment of inhibiting vascular restenosis in an individual.

- 5           16. Use of a composition of a pharmacologically acceptable Factor VII having at least one modification in its catalytic center, which modification substantially inhibits the ability of the modified Factor VII to activate plasma Factor X or IX, for inhibiting platelet deposition in an individual.

10

15

1 / 1

**FIGURE**

## INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT/US 94/05779

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 5 A61K37/46

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 15686 (ZYMOGENETICS) 17 September 1992 * see the whole document *	1-5
A	* " *	6-15
A	WO,A,91 11514 (ZYMOGENETICS) 8 August 1991 * see claims 1-23 *	1-15

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "E" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

- \* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* "&" document member of the same patent family

Date of the actual completion of the international search

7 October 1994

Date of mailing of the international search report

27 -10- 1994

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Isert, B

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No  
PCT/US 94/05779

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9215686	17-09-92	AU-A-	1449892	06-10-92
		EP-A-	0575464	29-12-93
		JP-T-	6504678	02-06-94
-----				
WO-A-9111514	08-08-91	AU-B-	651573	28-07-94
		AU-A-	7300291	21-08-91
		EP-A-	0521873	13-01-93
		JP-T-	5500161	21-01-93
		US-A-	5288629	22-02-94
-----				

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**